MetaCap

Madrigal Pharmaceuticals (MDGL) vs TG Therapeutics (TGTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

TG Therapeutics (TGTX) has outperformed Madrigal Pharmaceuticals (MDGL) over the past year, gaining 98.2% versus a loss of 30.8%. Over five years, MDGL leads with a +362.0% price change compared with +164.1% for TGTX. TG Therapeutics is the larger company by market cap ($9.57 billion vs $8.81 billion), about 1.1 times the size, while Madrigal Pharmaceuticals is growing revenue faster (+432.1% vs +87.3%).

On valuation, TG Therapeutics trades at a lower forward P/E (24.8x vs 36.5x for Madrigal Pharmaceuticals). TG Therapeutics converts more of its revenue into profit, with a net margin of 72.6% versus -30.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MDGL-30.82%TGTX+98.25%
+114%+38%-38%
Nov 21, 20251 yearNov 20, 2026
MDGL+360.07%TGTX+159.48%
+662%+272%-119%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MDGL versus TGTX key metrics
MetricMDGLTGTX
Share price$379.10$63.34
Market cap$8.81B$9.57B
1-day change-4.45%-2.37%
YTD return-34.90%+112.48%
1-year return-30.82%+98.25%
5-year return+361.98%+164.14%
P/E ratio (TTM)—94.54
Forward P/E36.5224.81
EPS (TTM)$-5.85$0.67
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$958.40M$616.29M
Revenue growth (YoY)+432.05%+87.32%
Net income (latest FY)$-288.28M$447.18M
Gross margin—83.66%
Operating margin-31.31%20.01%
Net margin-30.08%72.56%
52-week high$615.00$68.03
52-week low$353.54$26.76
Distance from 52-week high-38.36%-6.89%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+81.69%+9.61%
Average volume370.07K1.86M
Shares outstanding23.23M151.15M
Employees915399
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TGTX has outperformed MDGL by 129.1 percentage points over the past year.
  • TG Therapeutics is more profitable, keeping 72.6 cents of every revenue dollar as net income versus -30.1 cents for Madrigal Pharmaceuticals.
  • Madrigal Pharmaceuticals grew revenue faster in its latest fiscal year (+432.05% vs +87.32%).

About Madrigal Pharmaceuticals

MDGL stock →

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH.

Health Care · Biotechnology: Pharmaceutical Preparations · 915 employees

About TG Therapeutics

TGTX stock →

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

Health Care · Biotechnology: Pharmaceutical Preparations · 399 employees

MDGL vs TGTX FAQ

Which is bigger, Madrigal Pharmaceuticals or TG Therapeutics?

TG Therapeutics (TGTX) is larger, with a market capitalization of $9.57B compared with $8.81B for Madrigal Pharmaceuticals (MDGL).

Which stock has performed better over the past year, MDGL or TGTX?

TGTX returned +98.25% over the past 12 months, compared with -30.82% for MDGL (price return, excluding dividends). Past performance does not predict future results.

Are Madrigal Pharmaceuticals and TG Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons